

SmartPA Criteria Proposal

Drug/Drug Class:	Palynziq Clinical Edit
First Implementation Date:	April 18, 2019
Proposed Date:	June 16, 2022
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Palynziq® (pegvaliase-pqpz)

Why Issue Selected: Palynziq® (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management. PKU results from a deficiency of phenylalanine hydroxylase, leading to elevated blood and urine concentrations of phenylalanine and its metabolites. If untreated, PKU can cause neurological problems such as mental disability and seizures. PKU affects about 1 in 10,000-15,000 people in the United States, and it is estimated that there are about 11,000 adult PKU patients in the United States. Current therapies available for PKU, such as Kuvan® (sapropterin dihydrochloride) require patients to adhere to a restricted diet; Palynziq does not have a dietary requirement. Palynziq reduces blood phenylalanine concentrations by converting phenylalanine to ammonia and trans-cinnamic acid. Due to a high risk of hypersensitivity reactions, Palynziq comes with a REMS program and boxed warning. Doses should be administered under the supervision of a health care provider, and epinephrine should be available during treatment. Due to the high cost, possible adverse events, and specific approved indication, MO HealthNet will impose clinical criteria to ensure appropriate utilization of Palynziq.

Program-Specific Information:

Date Range FFS 4-1-2022 to 3-31-2022			
Drug	Claims	Spend	Average Spend per Claim
PALYNZIQ 2.5 MG/0.5 ML SYR	4	\$2,897.13	\$724.28
PALYNZIQ 10 MG/0.5 ML SYR	1	\$7,941.39	\$7,941.39
PALYNZIQ 20 MG/ML SYR	0	-	-

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Palynziq™ (pegvaliase-pqpz)
- Age range: All appropriate MO HealthNet participants aged 18 years or older

Approval Criteria

Initial Therapy:

- Documented diagnosis of phenylketonuria (PKU) in the past year **AND**
- Documented adequate therapeutic trial of Kuvan (sapropterin) defined as 180 days of therapy in the past year or ADE/ADRs to Kuvan therapy **AND**
- Documented baseline blood phenylalanine concentrations > 600 micromol/L

Continuation of Therapy:

- Initial approval of prior authorization is 1 year
- Renewal of prior authorization may be given following documentation of blood phenylalanine concentrations < 600 micromol/L or at least 20% less than baseline level

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Lack of an adequate response to therapy after 16 weeks of continuous treatment at the maximum dose of 60 mg daily
- Participant is currently pregnant
- Claim quantity exceeds 3 syringes per day

Required Documentation

Laboratory Results:
MedWatch Form:

X

Progress Notes:
Other:

X

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

1 year

References

- PALYNZIQ (pegvaliase-pqpz) injection [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; November 2020.
- IPD Analytics. Endocrine and Metabolic Agents: Phenylketonuria. Accessed May 16, 2022.
- Clinical Pharmacology. Pegvaliase: PALYNZIQ. Accessed May 16, 2022.

SmartPA Clinical Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.